Westham Competitors and Similar CompaniesClear all
Westham's competitors and similar companies include Alnylam, Merus and Aerie Pharmaceuticals.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. | ||
Founding Date | Founding Date 2006 | Founding Date 2002 | Founding Date 2003 | Founding Date 2005 |
Type | Type Private | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Dallas, US HQ Hod Hasharon, IL | Locations Utrecht, NL HQ Cambridge, US | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | |
Employees | Employees 1110% increase | Employees 1,32324% increase | Employees 172 | Employees 3808% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 36.5 b | Valuation ($) 3.6 b | Valuation ($) 722.2 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $43.9m (FY, 2023) | Revenue (est.) $194.1m (FY, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods $268.2m (FY, 2023) | Cost of goods N/A | Cost of goods $26.8m (FY, 2021) |
Gross profit | Gross profit N/A | Gross profit $1.6b (FY, 2023) | Gross profit $43.9m (FY, 2023) | Gross profit N/A |
Net income | Net income N/A | Net income ($440.2m) (FY, 2023) | Net income ($154.9m) (FY, 2023) | Net income ($74.8m) (FY, 2021) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 1.5b | Total funding raised $ 149.3m | Total funding raised $ 388.6m |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyMerus
HQ
Utrecht, NL
Employees
172
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View companyAerie Pharmaceuticals
HQ
Irvine, US
Employees
380↑ 8% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View company